Few people realise that the Emergency Use Authorisation (EUA)of the Pfizer-BioNTech Covid-19 Vaccine/BNT 162b2 was granted on the efficacy data of 170 patients. The 162 who received a placebo and 8 patients who were vaccinated formed the basis of the 95 per cent efficacy claims.
There has not been much discussion of these patients.
Already a subscriber? Log in
Easter flash sale:
10 issues for $1
Subscribe this Easter and get the next 10 issues of the magazine, plus website and app access, all for just $1.
- Weekly delivery of the magazine
- Unlimited access to spectator.com.au and app
- Spectator Australia podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Easter flash sale: 10 issues for $1
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
CLAIM OFFER 10 issues for $1Already a subscriber? Log in